|Videos|February 7, 2018

Governmental Intervention Needed to Ensure Hospital Mattresses Get Cleaned Appropriately

Edmond Hooker, MD, DrPH, stresses that the FDA and the CDC need to intervene to ensure that hospital mattresses get cleaned appropriately.

Edmond Hooker, MD, DrPH, professor, Health Services Administration at Xavier University, and emergency physician at the University of Cincinnati, stresses that the FDA and the CDC need to intervene to ensure that hospital mattresses get cleaned appropriately.

Interview Transcript (modified slightly for readability):

“I really do believe that the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) need to make an emergency of [hospital mattresses not being cleaned as well as they should be] and manage it.

This is the endoscope problem; it’s the exact same thing. People ignored it, and all of a sudden, we started piling up dead bodies. Guess what? We’ve got more dead bodies piling up from Clostridium difficile every day than any endoscope-related problem. And yet, they’re not managing it.

I think the CDC and the FDA need to say, ‘Immediately, you will high-level disinfect beds, mattresses—the whole thing. We’ve got to stop this. We can stop this.’ We’ve tried meeting with them. They’re like, ‘You know, it takes a long time to change regulations.’ And I get that, I understand bureaucracy, and I also understand that if they really see the emergency for what it is, they could change these regulations in months, not years.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
LMN-201 Reduces C difficile Recurrence
In the phase 2 RePreve trial, Lumen Bioscience’s investigational oral biologic LMN-201 plus standard antibiotics achieved global cure in 83.3% of patients with C difficile infection vs 36.4% with placebo, and cut recurrence sixfold (9.1% vs 55.6%) with no drug-related serious adverse events.